Search Results - "Koellerer, Christoph"

Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms by Peeken, Jan C., Jutzi, Jonas S., Wehrle, Julius, Koellerer, Christoph, Staehle, Hans F., Becker, Heiko, Schoenwandt, Elias, Seeger, Thalia S., Schanne, Daniel H., Gothwal, Monika, Ott, Christopher J., Gründer, Albert, Pahl, Heike L.

“…The transcription factor “nuclear factor erythroid 2” (NFE2) is overexpressed in the majority of patients with myeloproliferative neoplasms (MPNs). In murine…”
Get full text

Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice by Vorbach, Samuel, Gründer, Albert, Zhou, Fengbiao, Koellerer, Christoph, Jutzi, Jonas S., Simoni, Manuela, Riccetti, Laura, Valk, Peter J., Sanders, Mathijs A., Müller-Tidow, Carsten, Nofer, Jerzy-Roch, Pahl, Heike L., Potì, Francesco

“…Acute myeloid leukemia (AML) carries a 10–100 fold lower mutational burden than other neoplastic entities. Mechanistic explanations for why a low number of…”
Get full text

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells by Staehle, Anne Marie, Peeken, Jan Caspar, Vladimirov, Georg, Hoeness, Mirjam Elisabeth, Bojtine Kovacs, Sarolta, Karantzelis, Nikolaos, Gruender, Albert, Koellerer, Christoph, Jutzi, Jonas Samuel, Pahl, Heike Luise, Staehle, Hans Felix

“…The transcription factor NFE2 is overexpressed in most patients with myeloproliferative neoplasms (MPN). Moreover, mutations in NFE2, found in a subset of MPN…”
Get full text

The Cell Cycle Regulators CDK4, CDK6 and Cyclin D3 As Well As the Histone Methyltransferases MLL2 and MLL4 Constitute NF-E2 Target Genes That Participate in a Novel Regulatory Loop by Koellerer, Christoph, Pahl, Heike L., Wehrle, Julius

“…Background: Expression of the transcription factor and epigenetic modulator “nuclear factor erythroid-2” (NF-E2) is aberrantly elevated in patients with…”
Get full text

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations by Jutzi, Jonas Samuel, Basu, Titiksha, Pellmann, Maximilian, Kaiser, Sandra, Steinemann, Doris, Sanders, Mathijs A., Hinai, Adil S.A., Zeilemaker, Annelieke, Bojtine Kovacs, Sarolta, Koellerer, Christoph, Ostendorp, Jenny, Aumann, Konrad, Wang, Wei, Raffoux, Emmanuel, Cassinat, Bruno, Bullinger, Lars, Schlegelberger, Brigitte, Valk, Peter J.M., Pahl, Heike Luise

“…In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been…”
Get full text

The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2 by Siegwart, Laura C., Schwemmers, Sven, Wehrle, Julius, Koellerer, Christoph, Seeger, Thalia, Gründer, Albert, Pahl, Heike L.

“…•NFE2 regulates GATA2 and SCL/TAL1 expression.•One mechanism by which elevated NFE2 contributes to MPN phenotype SCL/TAL1 and GATA2 are aberrantly…”
Get full text

Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice by Talvard-Balland, Nana, Braun, Lukas M, Dixon, Karen O, Zwick, Melissa, Engel, Helena, Hartmann, Alina, Duquesne, Sandra, Penter, Livius, Andrieux, Geoffroy, Rindlisbacher, Lukas, Acerbis, Andrea, Ehmann, Jule, Köllerer, Christoph, Ansuinelli, Michela, Rettig, Andres, Moschallski, Kevin, Apostolova, Petya, Brummer, Tilman, Illert, Anna L, Schramm, Markus A, Cheng, Yurong, Köttgen, Anna, Duyster, Justus, Menssen, Hans D, Ritz, Jerome, Blazar, Bruce R, Boerries, Melanie, Schmitt-Gräff, Annette, Sariipek, Nurefsan, Van Galen, Peter, Buescher, Joerg M, Cabezas-Wallscheid, Nina, Pahl, Heike L, Pearce, Erika L, Soiffer, Robert J, Wu, Catherine J, Vago, Luca, Becher, Burkhard, Köhler, Natalie, Wertheimer, Tobias, Kuchroo, Vijay K, Zeiser, Robert

“…Leukemia relapse is a major cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). We tested the potential of targeting T cell (Tc)…”
Get full text

The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2 V617F mutated cells by Staehle, Anne Marie, Peeken, Jan Caspar, Vladimirov, Georg, Hoeness, Mirjam Elisabeth, Bojtine Kovacs, Sarolta, Karantzelis, Nikolaos, Gruender, Albert, Koellerer, Christoph, Jutzi, Jonas Samuel, Pahl, Heike Luise, Staehle, Hans Felix

“…The transcription factor NFE2 is overexpressed in most patients with myeloproliferative neoplasms (MPN). Moreover, mutations in NFE2, found in a subset of MPN…”
Get full text